BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts

European Heart Journal

Volumn 30, Issue 13, 2009, Pages 1607-1613

  Krieg, Thomas ^a   Liu, Yanping ^c   Rütz, Thomas ^a   Methner, Carmen ^a   Yang, Xi Ming ^c   Dost, Turhan ^c   Felix, Stephan B ^a   Stasch, Johannes Peter ^b   Cohen, Michael V ^c   Downey, James M ^c  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b BAYER PHARMA AG   (Germany)

^c UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

BAY 58 2667; Cardioprotection; Guanylyl cyclase; Protein kinase G; Reperfusion

Indexed keywords

4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; 5 HYDROXYDECANOIC ACID; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; KT 5823; N(G) NITROARGININE METHYL ESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISOLATED HEART; LOADING DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY;

ANIMALS; BENZOIC ACIDS; CARDIOTONIC AGENTS; CYCLIC AMP; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; GUANYLATE CYCLASE; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; RABBITS; RATS; RATS, WISTAR;

EID: 67650094306     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp143     Document Type: Article

References (24)

1. Burley DS, Ferdinandy P, Baxter GF. Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. Br J Pharmacol 2007;152:855-869.
2. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-1136.
3. Zhao Z-Q, Corvera JS, Halkos ME, Kerendi F, Wang N-P, Guyton RA, Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285:H579-H588.
4. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I, Aupetit J-F, Bonnefoy E, Finet G, Andre-Fouet X, Ovize M. Postconditioning the human heart. Circulation 2005;112:2143 -2148.
5. Tissier R, Cohen MV, Downey JM. Protecting the acutely ischemic myocardium beyond reperfusion therapies: are we any closer to realizing the dream of infarct size elimination? Arch Mal Coeur Vaiss 2007;100:794-802.
6. ATP channel opening and leads to cardioprotection. Am J Physiol Heart Circ Physiol 2004;286:H468-H476.
7. DowneyJM, Krieg T, Cohen MV. Mapping preconditioning's signaling pathways: an engineering approach. Ann N Y Acad Sci 2008;1123:187- 196.
8. Yang X-M, Philipp S, Downey JM, Cohen MV. Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol 2006;101:311 -318.
9. BurleyDS, Baxter GF. B-type natriuretic peptide at earlyreperfusion limits infarct size in the rat isolated heart. Basic Res Cardiol 2007;102:529-541.
10. Maas O, Donat U, Frenzel M, Rütz T, Kroemer HK, Felix SB, Krieg T. Vardenafil protects isolated rat hearts at reperfusion dependent on GC and PKG. Br J Pharmacol 2008;154:25-31.
11. ATP channels when administered at reperfusion following ischemia in rabbits. J Mol Cell Cardiol 2007;42:453 -458.
12. Stasch J-P, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroeder W, Schröder H, Stahl E, Steinke W, Wunder F. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 2002;136:773-783.
13. Peart JN, Gross ER, Reichelt ME, Hsu A, HeadrickJP, Gross GJ. Activation of kappa-opioid receptors at reperfusion affords cardioprotection in both rat and mouse hearts. Basic Res Cardiol 2008;103:454-463.
14. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch J-P, Burnett JC Jr. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension 2007;49:1128-1133.
15. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H, Stasch J-P, Gnoth MJ, Seeger W, Grimminger F, Schermuly RT. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006;113:286-295.
16. Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HHHW, Stasch J-P. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006;5:755-768.
17. Costa ADT, Garlid KD, West IC, Lincoln T, Downey JM, Cohen MV, Critz SD. Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ Res 2005;97:329-336.
18. 2b agonists by protein kinase C. Am J Physiol Heart Circ Physiol 2008;295:H1288-H1295.
19. Zaccolo M, Movsesian MA. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res 2007;100:1569-1578.
20. Makaula S, Lochner A, Genade S, Sack MN, Awan MM, Opie LH. H-89, a nonspecific inhibitor of protein kinase A, promotes post-ischemic cardiac contractile recovery and reduces infarct size. JCardiovasc Pharmacol 2005;45:341 -347.
21. Das M, Parker JE, Halestrap AP. Matrix volume measurements challenge the existence of diazoxide/glibencamide-sensitive Katp channels in rat mitochondria. JPhysiol 2003;547:893-902.
22. Xu Z, Downey JM, Cohen MV. Timing and duration of administration are crucial for antiinfarct effect of AMP 579 infused at reperfusion in rabbit heart. Heart Dis 2003;5:368-371.
23. YangX-M,ProctorJB,CuiL,KriegT,DowneyJM,CohenMV.Multiple,briefcor- onary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. JAm Coll Cardiol 2004;44:1103-1110.
24. Lim SY, Davidson SM, Hausenloy DJ, Yellon DM. Preconditioning and postcondi- tioning: the essential role of the mitochondrial permeability transition pore. Cardiovasc Res 2007;75:530-535.